Pulmonary Hypertension Drug Helps To Treat Cancer by Pooja Shete on December 22, 2020 at 8:35 PM
In the trials involving ovarian, breast cancer, pancreatic, and leukemia cancer cell lines, a drug used to treat pulmonary hypertension can significantly reduce the capacity of tumor cells to migrate and invade other tissues. In mice having an aggressive form of breast cancer, the drug showed reduced incidence of metastasis in the lungs and liver by 47% and increase survival as compared with untreated animals.
The research conducted at the University of São Paulo s Biomedical Sciences Institute (ICB-USP) in Brazil is published in
Scientific Reports
The drug called ambrisentan is used to treat pulmonary hypertension. It is an inhibitor of the endothelin type A receptor, which plays a role in increasing the blood pressure. Pulmonary hypertension is caused by autoimmune disorders like lupus and systemic sclerosis. According to the laboratory studies, the drug pr
E-Mail
By André Julião | Agência FAPESP - A drug used to treat pulmonary hypertension significantly reduced the capacity of tumor cells to migrate and invade other tissues in trials involving pancreatic, ovarian, breast cancer, and leukemia cell lines. Furthermore, in mice with an aggressive form of breast cancer, the drug reduced the incidence of metastasis in the liver and lungs by 47% and lengthened survival compared with untreated animals.
The study is
Scientific Reports. The drug ambrisentan is an inhibitor of the endothelin type A receptor, which is known to play a role in vasoconstriction, so the drug is used to treat pulmonary hypertension [
Pulmonary hypertension drug may become a treatment option for cancer
A drug used to treat pulmonary hypertension significantly reduced the capacity of tumor cells to migrate and invade other tissues in trials involving pancreatic, ovarian, breast cancer, and leukemia cell lines. Furthermore, in mice with an aggressive form of breast cancer, the drug reduced the incidence of metastasis in the liver and lungs by 47% and lengthened survival compared with untreated animals.
The study is published in
Scientific Reports. The drug ambrisentan is an inhibitor of the endothelin type A receptor, which is known to play a role in vasoconstriction, so the drug is used to treat pulmonary hypertension [